share_log

Takeda Gains Approval For HYQVIA In Japan To Treat Immunodeficiency

Benzinga ·  Dec 27 14:39
  • HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase] is the First and Only Facilitated Subcutaneous Immunoglobulin (fSCIG) Approved in Japan for Agammaglobulinemia and Hypogammaglobulinemia
  • Administration of Recombinant Human Hyaluronidase Prior to Immunoglobulin Facilitates Subcutaneous Infusion of Larger Volumes, Potentially Reducing Frequency and Giving Patients More Flexibility
  • Approval Expands Takeda's Portfolio of Differentiated Immunoglobulin Therapies and Reflects the Company's Commitment to Bring High-Quality Plasma-Derived Therapies to Patients in Japan
Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment